CORT
$33.26+1.08 (+3.36%)
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Recent News
H.C. Wainwright Cuts Corcept Therapeutics Incorporated (CORT) Price Target, Keeps Buy Rating
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best under-the-radar stocks to buy according to hedge funds. On February 25, H.C. Wainwright reduced its price target on Corcept Therapeutics Incorporated (NASDAQ:CORT) from $67 to $60 and maintained its Buy rating on the stock. The company reported Q4 2025 revenue of $202.1 million, which fell short […]
1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.
Corcept Therapeutics Lawsuits And CRL Put Relacorilant Story Under Pressure
Corcept Therapeutics (NasdaqCM:CORT) is facing multiple securities class action lawsuits following the FDA's Complete Response Letter rejecting relacorilant for Cushing’s syndrome. Plaintiffs allege the company misrepresented its regulatory communications and the drug's approval prospects in public statements and filings. A federal investigation has been opened alongside the civil lawsuits, increasing legal and regulatory scrutiny of the company. For investors watching Corcept Therapeutics,...
Is Corcept Therapeutics (CORT) Pricing Reflect Its Sharp One Year Share Price Decline
If you are trying to figure out whether Corcept Therapeutics at around US$35.78 is a bargain or just fairly priced, you are in the right place. The stock has been volatile recently, with a 4.5% gain over the last 7 days, a 22.6% decline over the last 30 days, a 6.3% decline year to date, and a 40.2% decline over the last year, following an 82.9% return over 3 years and 50.0% over 5 years. These moves have kept Corcept in focus as investors react to ongoing developments around its core...
Corcept Therapeutics Incorporated Q4 2025 Earnings Call Summary
Moby summary of Corcept Therapeutics Incorporated's Q4 2025 earnings call